Preliminary results of an observational program for estimating the duration of bevacizumab therapy in patients with metastatic colorectal cancer in daily clinical practice

  • Authors: Poddubnaya IV1, Bobrovskaya EV2, Vladimirova LY.3, Gordeev SS4, Davidenko IS5, Emelyanov SA6, Zharkova OV7, Koroleva IA8, Krasilnikova SY.9, Maikoparova SC.10, Malysheva TA11, Modestov AA2, Morozov AN12, Stachenko GB13, Strygina EA5, Tlish EK.14, Feoktistova PS15, Chichkanova AS16, Sherman NZ17
  • Affiliations:
    1. ГБОУ ДПО РМАПО Минздрава РФ, Москва
    2. ГУЧ КГБУЗ Красноярский краевой клинический онкологический диспансер им. А.И.Крыжановского
    3. Ростовский НИОИ Минздрава РФ
    4. ФГБУ РОНЦ им. Н.Н.Блохина РАМН, Москва
    5. Краснодарский краевой онкологический диспансер
    6. Республиканский клинический онкологический диспансер, Ижевск
    7. Кемеровский областной клинический онкологический диспансер
    8. Самарский областной клинический онкологический диспансер
    9. Свердловский областной онкологический диспансер
    10. Адыгейский республиканский онкологический диспансер, Майкоп
    11. Пермский краевой онкологический диспансер
    12. Тольяттинская городская клиническая больница №5
    13. Омский областной клинический онкологический диспансер
    14. Республиканский онкологический диспансер, Грозный
    15. Нижневартовский городской онкологический диспансер
    16. Нижегородский областной онкологический диспансер
    17. Кировский областной клинический онкологический диспансер
  • Issue: Vol 15, No 1 (2013)
  • Pages: 5-9
  • Section: Articles
  • URL: https://journals.rcsi.science/1815-1434/article/view/26877
  • ID: 26877

Cite item

Full Text

Abstract

Objective: to estimate the average duration of therapy with Avastin (bevacizumab) in patients with metastatic colorectal cancer (mCRC) in the daily clinical practice of cancer care facilities in Russia. Methods. The observational program is being implemented on the initiative of the Russian Medical Academy for Postgraduate education RF (Moscow) and it is based on the results of treating patients with mCRC in 24 clinical centers from different regions of the Russian Federation. The observational program includes patients receiving drug treatment for mCRC in accordance with the local standards and guidelines. Program patient enrolment has not been over yet. The paper presents preliminary results. Results. As of March 1, 2013, the program enrolled 117 patients, including 43 with rectal cancer and 74 with colon cancer. At baseline 70 (60%) patients had synchronous distant metastases and 47 (40%) patients developed synchronous distant metastases after primary radical surgery. At the analysis, 112 patients were treated with bevacizumab in combination with different chemotherapy (CT) regimens; 25 patients received more than the 1 line of CT, in 8 of them bevacizumab was discontinued (because of disease progression in 6 cases); 33 (29%) patients were switched to bevacizumab monotherapy during treatment. The effect of CT with simultaneous administration of 7–10 infusions of bevacizumab was preserved in 73% of the patients; 4 and 27% showed complete and partial responses, respectively; stabilization was noted in 42%. Sixty-three (56%) patients received symptomatic therapy. Adverse events were observed in 18 (16%) patients, 13 of them had grade 4 reactions. Conclusion. Targeted therapy with bevacizumab is in considerable use in the health care facilities of the Russian Federation. The addition of bevacizumab to CT does not increase toxicity of CT. The combination of bevacizumab and standard CT regimens can achieve high disease control rates.

About the authors

I V Poddubnaya

ГБОУ ДПО РМАПО Минздрава РФ, Москва

д-р мед. наук, проф., чл.-кор. РАМН, зав. каф. онкологии ГБОУ ДПО РМАПО Минздрава РФ, Москва

E V Bobrovskaya

ГУЧ КГБУЗ Красноярский краевой клинический онкологический диспансер им. А.И.Крыжановского

L Yu Vladimirova

Ростовский НИОИ Минздрава РФ

д-р мед. наук, проф.

S S Gordeev

ФГБУ РОНЦ им. Н.Н.Блохина РАМН, Москва

канд. мед, наук

I S Davidenko

Краснодарский краевой онкологический диспансер

д-р мед. наук

S A Emelyanov

Республиканский клинический онкологический диспансер, Ижевск

O V Zharkova

Кемеровский областной клинический онкологический диспансер

канд. мед. наук

I A Koroleva

Самарский областной клинический онкологический диспансер

д-р мед. наук

S Yu Krasilnikova

Свердловский областной онкологический диспансер

S Ch Maikoparova

Адыгейский республиканский онкологический диспансер, Майкоп

канд. мед. наук

T A Malysheva

Пермский краевой онкологический диспансер

A A Modestov

ГУЧ КГБУЗ Красноярский краевой клинический онкологический диспансер им. А.И.Крыжановского

A N Morozov

Тольяттинская городская клиническая больница №5

G B Stachenko

Омский областной клинический онкологический диспансер

E A Strygina

Краснодарский краевой онкологический диспансер

E Kh Tlish

Республиканский онкологический диспансер, Грозный

канд. мед. наук

P S Feoktistova

Нижневартовский городской онкологический диспансер

A S Chichkanova

Нижегородский областной онкологический диспансер

N Z Sherman

Кировский областной клинический онкологический диспансер

References

  1. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2011 г. (заболеваемость и смертность). М.: ФГБУ МНИОИ им. П.А.Герцена, 2013.
  2. SEER stat fact sheets: colon and rectum. http://seer.cancer.gov/statfacts/html/colorect.html
  3. Saltz L.B. et al. Bevacizumab in combination with oxaliplatin - based chemotherapy as first - line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26 (12): 2013–9.
  4. Cutsem Van E et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first - line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29 (15): 2011–9.
  5. Kerbel R.S., Folkman J. Clinical translation of antiangiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727–39.
  6. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncolog 2000; 5: 3–10.
  7. Jain R.K. Normalizing tumor vasculature with anti - angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987–9.
  8. Bergers G, Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401–10.
  9. Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350 (23): 2335–42.
  10. Giantonio B.J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25 (12): 1539–44.
  11. Van Cutsem E et al. Safety and efficacy of first - line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20 (11): 1842–7.
  12. Kozloff M et al. Clinical outcomes associated with bevacizumab - containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncolog 2009; 14 (9): 862–70.
  13. Cohn A.L., Bekaii-Saab T et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). J Clin Oncol 2010; 28 (15): 3596.
  14. Arnold D, Thierry A, Bennouna J. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). J Clin Oncol 2012; 30: CRA 3503.
  15. Tabernero J, Aranda E, Gomez A. Phase III study of first - line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single - agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC). The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors – TTD). J Clin Oncol 2010; 28 (15): 3501.
  16. Rosati G et al. XELOX and bevacizumab followed by single - agent bevacizumab as maintenance therapy as first - line treatment in elderly patients with advanced colorectal cancer: the boxe study. Cancer Chemother Pharmacol 2013; 71 (1): 257–64.
  17. Kobunai T et al. The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real - time PCR. Biochem Biophys Res Commun 2010; 395 (1): 158–62.
  18. Brink M et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogen 2003; 24 (4): 703–10.

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies